Medcorp Limited

—

What it is

Medcorp is an operator of private healthcare facilities in north-west Trinidad, including St Clair Medical Centre, Goodhealth Medical Centre, the Brian Lara Cancer Treatment Centre, and Doctors Radiology Centre.

It is the largest private healthcare facility in the Republic of Trinidad and Tobago, offering services from cardiac catheterisation, cardiology, dentistry, intensive care, maternity, pharmacy, surgical services, radiology, dialysis, physiotherapy, and endoscopy — the full breadth of a tertiary hospital system, privately run.

The current listed entity was formed on 1 October 2024 through the amalgamation of the former Medcorp Limited with its wholly owned subsidiaries Cancer Centre of the Caribbean Limited and Medical X-Ray and Diagnostic Clinic Limited — a tidying of the group structure just before the IPO.

—

Who owns it

Before the IPO, Medcorp was wholly owned by its existing shareholders, with 65.51% of ordinary shares held by connected shareholders — that is, company insiders and the founding medical families.

The IPO launched 27 May 2025, offering 350,000 ordinary shares at TTD 48 (US$7)each, which were fully subscribed. That public offer raised TTD 16.8m (≈ US$2.5m) and created a free float, but the founding bloc retained its commanding majority.

The connected shareholders — led by Dr Kongshiek Achong Low, Dr Dinesh Mor, and associated families including the Yufe and Tang Nian families — remain the controlling group; their precise post-IPO percentage is not disclosed in available sources.

—

Who runs it

Dr Dinesh Mor serves as executive chairman of Medcorp. The board named in the prospectus includes Dr Kongshiek Achong Low, Mr John Tang Nian, Dr Boris Yufe, Mr Richard Yufe, and Mr Renard Teelucksingh, alongside Mor — a board drawn largely from the founding medical and business families.

In May 2026, Mr Gerrard Lee-Inniss resigned as an independent director at Medcorp. A chief executive officer (CEO) or CFO separate from the executive chairman is not disclosed in available sources.

—

The money, in plain words

In the year to December 2025, Medcorp took in TTD 121.7m (≈ US$18.1m) in revenue — roughly flat from the TTD 122.2m (US$18 mn) the year before. It kept about 15 cents of profit from every dollar of sales, a net profit margin of 14.9% (our calculation), which is solid for a hospital operator.

For every dollar of shareholders’ capital on the books, the company earned back roughly 24 cents — a return on equity of approximately 24% (our calculation), strong by any regional comparison. At the current price of TTD 41, (US$6)the stock trades at 16.1 times annual earnings (a price-to-earnings ratio of 16.1×) and pays a dividend of TTD 2.00 (US$0.30)per share annually, a dividend yield of 4.88% — attractive against local bank deposits.

It is worth noting that 2023 showed an unusually high net profit of TTD 57.1m (US$8 mn), largely reflecting the corporate restructuring ahead of the IPO rather than a sudden surge in hospital revenues; 2024 and 2025 earnings of TTD 15 (US$2)–18m represent the underlying operating run-rate.

—

What it is doing now

In the quarter ended 31 March 2026, Medcorp reported total comprehensive income of TTD 10.88m (US$2 mn) — an improvement over the TTD 9.5m (US$1 mn) recorded for the same period in 2025. That is encouraging: the business is growing quarter-on-quarter even as full-year revenues have been broadly flat.

Director John Tang Nian said the listing supports the company’s long-term growth objectives, with IPO proceeds earmarked to provide additional capital for strategic expansion plans set out in the prospectus. Republic Wealth Management Limited served as lead broker, with Republic Bank Limited as lead investment adviser.

—

What to watch

• Revenue growth: Sales have been essentially flat for three years (TTD 122 (US$18)–127m). Whether the IPO capital accelerates expansion — a new facility or service line — is the key test.
• Ownership clarity: The post-IPO ownership split among connected shareholders has not been disclosed publicly; any regulatory filing that names exact stakes will sharpen the governance picture.
• Share price drift: The stock opened at TTD 48 (US$7)(IPO price) and was trading at TTD 41 (US$6)by end-June 2026 — a decline of about 15% — while Q1 2026 profits improved. That gap between operating momentum and market price is worth monitoring.
• Board stability: The May 2026 resignation of the sole named independent director, Mr Gerrard Lee-Inniss, reduces independent oversight; how quickly a replacement is named matters to minority shareholders.
• Second AGM (July 2026): The Second Annual Meeting of Shareholders of Medcorp Limited is scheduled for 17 July 2026 at Chaconia Event Centre, Maraval. The full-year 2025 audited accounts and any capital deployment update will be the centrepiece.

—

This is news, not investment advice.